4-chloro-1-(piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one | 783368-08-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 4-chloro-1-(piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
• 英文别名: 4-chloro-1-(piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one；5-chloro-1-piperidin-4-yl-1,3-dihydro-2H-benzimidazol-2-one；4-chloro-1-piperidin-4-yl-1,3-dihydro-2H-benzimidazol-2-one；4-Chloro-1-(piperidin-4-yl)-1,3-dihydro-2h-benzimidazol-2-one；7-chloro-3-piperidin-4-yl-1H-benzimidazol-2-one
• CAS: 783368-08-1
• 化学式: C₁₂H₁₄ClN₃O
• 分子量: 251.716
• InChiKey: NFYOBQLGMCKJID-UHFFFAOYSA-N

物化性质

• 密度：
  1.323±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  44.4
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-chloro-1-(piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one 在 titanium(IV) isopropylate 作用下， 以 乙醇 为溶剂， 反应 24.5h， 生成 4-chloro-1-(1-(4-bromo-2-fluorobenzyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one mesylate salt
  参考文献：
  名称：

  Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias

  摘要：

  While mu opioid receptor (MOR) agonists are especially effective as broad-spectrum pain relievers, it has been exceptionally difficult to achieve a clear separation of analgesia from many problematic side effects. Recently, many groups have sought MOR agonists that induce minimal beta arrestin-mediated signaling because MOR agonist-treated beta arrestin2 knockout mice were found to display enhanced antinociceptive effects with significantly less respiratory depression and tachyphylaxis. Substantial data now exists to support the premise that G protein signaling biased MOR agonists can be effective analgesic agents. We recently showed that, within a chemical series, the degree of bias correlates linearly with the magnitude of the respiratory safety index. Herein we describe the synthesis and optimization of piperidine benzimidazolone MOR agonists that together display a wide range of bias (G/beta arr2). We identify structural features affecting potency and maximizing bias and show that many compounds have desirable properties, such as long half-lives and high brain penetration.

  DOI：

  10.1021/acs.jmedchem.8b01136
• 作为产物：
  描述：

  2-氯-6-氟硝基苯 在 铁粉 、 碳酸氢钠 、 potassium carbonate 、 氯化铵 、 三氟乙酸 、 potassium iodide 作用下， 以 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 35.5h， 生成 4-chloro-1-(piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
  参考文献：
  名称：

  [EN] FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME
  [FR] COMPOSÉ CONTENANT UN CYCLE FUSIONNÉ, SON APPLICATION, ET COMPOSITION LE CONTENANT
  [ZH] 一种含稠环的化合物、其应用及含其的组合物

  摘要：

  一种含稠环的化合物、其应用及含其的组合物，具体为一种如式(II)所示的含稠环的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物，该类化合物具有较佳的STAT5抑制活性。

  公开号：

  WO2022083731A1

文献信息

• Benzodiazepine cgrp receptor antagonists
  申请人：Burgey S. Christopher

  公开号：US20060148790A1

  公开（公告）日：2006-07-06

  The present invention is directed to compounds of Formula I: (where variables R 1 , R 2 , R 3 , R 6 , R 7 , G, J, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及化合物I的公式：（其中变量R1，R2，R3，R6，R7，G，J，W，X和Y的定义如本文所述），用作CGRP受体拮抗剂，并用于治疗或预防CGRP参与的疾病，例如头痛，偏头痛和群头痛。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物的用途。
• Benzimidazolone derivatives
  申请人：——

  公开号：US20040147506A1

  公开（公告）日：2004-07-29

  This invention relates to benzimidazolone derivatives, represented by compounds of a general formula [I] 1 [in which R 1 and R 2 stand for, e.g., hydrogen atoms; R 3a , R 3b , R 4 , R 5 stand for, e.g., hydrogen atoms and alkyl groups; R 6 stands for e.g., aryl or heteroaryl groups; A ring stands for 5- to 8-membered aliphatic heterocyclic ring containing one nitrogen atom; and Z stands for carbonyl group or sulfonyl group]. The benzimidazolone derivatives of the invention exhibit antagonism to muscarinic acetylcholine receptors, and are useful as treating agent and/or prophylactic of Parkinson's disease, drug-induced parkinsonism, dystonia, akinesia, pancreatitis, bilestone/cholecystitis, biliary dyskinesia, achalasia, pain, itch, cholinergic urticaria, irritable bowel syndrome, vomiting, nausea, dizziness, Meniere's disease, motion sickness and urinary disturbance.

  本发明涉及苯并咪唑酮衍生物，其由一般式[I]中的化合物表示，其中R1和R2代表氢原子；R3a、R3b、R4、R5代表氢原子和烷基基团；R6代表芳基或杂环芳基基团；A环代表含有一个氮原子的5-至8-成员脂肪族杂环环；Z代表羰基团或磺酰基团。本发明的苯并咪唑酮衍生物表现出对肌动蛋白乙酰胆碱受体的拮抗作用，可用作帕金森病、药物诱导的帕金森综合征、肌张力障碍、运动障碍、胰腺炎、胆石/胆囊炎、胆道运动障碍、食管失弛缓症、疼痛、瘙痒、胆碱能荨麻疹、肠易激综合征、呕吐、恶心、眩晕、梅尼埃病、晕动病和尿液障碍的治疗剂和/或预防剂。
• Cgrp receptor antagonists
  申请人：Burgey S. Christopher

  公开号：US20060194783A1

  公开（公告）日：2006-08-31

  The present invention is directed to compounds of Formula I and Formula II: (where variables R1, R2, R3, R4, R6, A, B, G, J, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及式I和式II的化合物：（其中变量R1、R2、R3、R4、R6、A、B、G、J、W、X和Y如本文所定义），其作为CGRP受体拮抗剂在治疗或预防涉及CGRP的疾病，例如头痛、偏头痛和群发性头痛中有用。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗涉及CGRP的这些疾病中使用这些化合物和组合物的用途。
• Benzodiazepine CGRP receptor antagonists
  申请人：Merck & Co, Inc.

  公开号：US07196079B2

  公开（公告）日：2007-03-27

  The present invention is directed to compounds of Formula I: (where variables R1, R2, R3, R6, R7, G, J, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及一种化合物，其化学式为I：（其中变量R1、R2、R3、R6、R7、G、J、W、X和Y如本文所定义），该化合物可用作CGRP受体的拮抗剂，可用于治疗或预防CGRP参与的疾病，如头痛、偏头痛和丛集性头痛。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗CGRP参与的这些疾病中的应用。
• CGRP receptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US07205292B2

  公开（公告）日：2007-04-17

  The present invention is directed to compounds of Formula I and Formula II: (where variables R1, R2, R3, R4, R6, A, B, G, J, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及公式I和公式II的化合物：（其中变量R1、R2、R3、R4、R6、A、B、G、J、W、X和Y的定义如本文所述），用作CGRP受体的拮抗剂，并用于治疗或预防CGRP参与的疾病，如头痛、偏头痛和集群头痛。本发明还涉及包含这些化合物的制药组合物，以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物的用途。